News

February 24, 2017 12:00 pm
REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation - Celgene International Sàrl, a wholly-owned...
February 24, 2017 10:45 am
IMF President and Co-Founder Susie Novis Durie and the IMF Chairman of the Board Dr. Brian G.M. Durie are in Reykjavik, Iceland this week to work alongside the iStopMM research team.
February 23, 2017 12:00 pm
Knowing as much as you can about your cancer can be scary, but Kathy Giusti explains that this information can be vital to bring patients the right, specific precision treatments. Read more
February 22, 2017 12:00 pm
FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) - Celgene Corporation announced that the U.S. Food and Drug...

Pages